Sjögren's disease & overlap diseases
Anti-aquaporin-5 and anti-poly-U-binding-factor-60kDa protein antibodies in primary Sjögren's disease patients: preliminary data and correlation with disease activity indices
Authors' conclusion
Our pilot study confirms that anti-AQP5 antibodies may discriminate pSjD patients with high disease activity.
Study context
- Population
- Patients with primary Sjögren's disease and healthy donors
- Participants
- 36 vs 8
- Exposure
- Primary Sjögren's disease (pSjD) patients vs healthy donors; high vs low-moderate disease activity
- pSjDn = 36
- Healthy donors (HD)n = 8reference
- Outcome
- Occurrence of serum anti-AQP5 and anti-PUF60 antibodies and their correlations with clinical and laboratory features of pSjD
Methodological detailspilot study, multivariate stepwise backward multiple regression
- Pilot study
- Multivariate stepwise backward multiple regression
Main finding
As reported in the abstract
Serum anti-AQP5 and anti-PUF60 antibody levels
- Anti-AQP5 and anti-PUF60 antibody levels not significantly different between pSjD and HD
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Anti-AQP5 antibody levels by disease activity in pSjDHigh disease activity vs Low-moderate disease activity | P < 0.001 |
- Anti-AQP5 antibody levels by disease activity in pSjD: significantly higher anti-AQP5 levels with high disease activity (n. 10)
Variables associated with high disease activity (logistic regression)
- anti-AQP5, OR
- 128.9 (95% CI 2.7-615)
- CRP, OR
- 12.9 (95% CI 1.2-137.2)
- C4 <10 mg/dl, OR
- 60 (95% CI 1.1-318.9)
- Adjusted for clinical covariates
Original publication
Anti-aquaporin-5 and anti-poly-U-binding-factor-60kDa protein antibodies in primary Sjögren's disease patients: preliminary data and correlation with disease activity indices. Clin Exp Rheumatol. Published 8 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →